|
1
|
Dearing KR, Sangal A and Weiss GJ:
Maintaining clarity: Review of maintenance therapy in non-small
cell lung cancer. World J Clin Oncol. 5:103–113. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hill C: Cancer prevention and screening.
Bull Cancer. 100:547–554. 2013.(In French).
|
|
3
|
Chen YT, Feng B and Chen LB: Update of
research on drug resistance in small cell lung cancer chemotherapy.
Asian Pac J Cancer Prev. 13:3577–3581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Curry NL, Mino-Kenudson M, Oliver TG, et
al: Pten-null tumors cohabiting the same lung display differential
AKT activation and sensitivity to dietary restriction. Cancer
Discov. 3:908–921. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park YH, Kim SU, Lee BK, et al: Prx I
suppresses K-ras-driven lung tumorigenesis by opposing
redox-sensitive ERK/cyclin D1 pathway. Antioxid Redox Signal.
19:482–496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Salminen A, Lehtonen M, Suuronen T, et al:
Terpenoids: natural inhibitors of NF-kappaB signaling with
anti-inflammatory and anticancer potential. Cell Mol Life Sci.
65:2979–2999. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peterson-Roth E, Brdlik CM and Glazer PM:
Src-induced cisplatin resistance mediated by cell-to-cell
communication. Cancer Res. 69:3619–3624. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reynolds C, Spira AI, Gluck L, et al:
Sunitinib malate in previously untreated, nonsquamous, non-small
cell lung cancer patients over the age of 70 years: results of a
Phase II trial. Invest New Drugs. 31:1330–1338. 2013.PubMed/NCBI
|
|
9
|
Wei L, Dai Q, Zhou Y, et al: Oroxylin A
sensitizes non-small cell lung cancer cells to anoikis via
glucose-deprivation-like mechanisms: c-Src and hexokinase II.
Biochim Biophys Acta. 1830:3835–3845. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Melguizo C, Prados J, Luque R, et al:
Modulation of multidrug resistance gene expression in peripheral
blood mononuclear cells of lung cancer patients and evaluation of
their clinical significance. Cancer Chemother Pharmacol.
71:537–541. 2013. View Article : Google Scholar
|
|
11
|
Zhang B, Liu M, Tang HK, et al: The
expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in
tongue squamous cell carcinoma. J Oral Pathol Med. 41:141–148.
2012.
|
|
12
|
Li XQ, Li J, Shi SB, et al: Expression of
MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell
lung cancer patients receiving postoperative cisplatin-based
chemotherapy. Int J Biol Markers. 24:230–237. 2009.
|
|
13
|
Wang J, Zhang J, Zhang L, et al:
Expression of P-gp, MRP, LRP, GST-π and TopoIIα and intrinsic
resistance in human lung cancer cell lines. Oncol Rep.
26:1081–1089. 2011.
|
|
14
|
Banerjee A, Qian P, Wu ZS, et al: Artemin
stimulates radio- and chemo-resistance by promoting
TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary
carcinoma cells. J Biol Chem. 287:42502–42515. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han Y, Wang XB, Xiao N and Liu ZD: mRNA
expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS
and TUBB3 in postoperative patients with non-small cell lung
cancer. Asian Pac J Cancer Prev. 14:2987–2990. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu JL, Wang Y, Jiang J, et al: Inhibition
of survivin expression and mechanisms of reversing drug-resistance
of human lung adenocarcinoma cells by siRNA. Chin Med J (Engl).
123:2901–2907. 2010.PubMed/NCBI
|
|
17
|
Munić V, Kelnerić Z, Mikac L and Eraković
Haber V: Differences in assessment of macrolide interaction with
human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase
activity and cellular accumulation assays. Eur J Pharm Sci.
41:86–95. 2010.PubMed/NCBI
|
|
18
|
Wei HB, Hu J, Shang LH, et al: A
meta-analytic review of ERCC1/MDR1 polymorphism and
chemosensitivity to platinum in patients with advanced non-small
cell lung cancer. Chin Med J (Engl). 125:2902–2907. 2012.PubMed/NCBI
|
